Vanadate and peroxovanadate were recently reported to exert maximal or even supramaximal (peroxovanadate) insulin-like effects in rat adipocytes. To evaluate the response in human cells, isolated human adipocytes were exposed to insulin or various concentrations of vanadate (0-10retool/I) or peroxovanadate (0-5 retool/l). Neither vanadate nor peroxovanadate affected 125I-insulin binding and insulin sensitivity. Vanadate exerted no apparent effect on 14C-U-glucose uptake, whereas 0.1 mmol/1 peroxovanadate exerted a full insulin-like response (p < 0.001). No additive response was observed by combining either vanadate or peroxovanadate with insulin. Peroxovanadate at 0.1 mmol/1 was as effective as insulin in inhibiting isoproterenol-stimulated lipolysis. Neither peroxovanadate nor insulin-inhibited lipolysis stimulated by N6-monobutyryl-cAMR an analogue which is not hydrolysed by the cAMP-phosphodiesterase. It is concluded that peroxovanadate, but not vanadate, elicits a full insulin-like response in human adipocytes.
Traces of vanadate are found in most plants and mammalian tissues. Vanadate is also an essential nutrient [1] , which stimulates mitogenic activity in cell cultures [2] . However, the physiological function of vanadate is still unclear (see [3] ). The effects exerted by vanadate include inhibition of ion transport ATP-ases [4] and phosphotyrosine phosphatase [5] . In recent years, increasing interest has been focused on the insulin-like activity of vanadate in various tissues and cells[@ Since insulin resistance in experimental animals may be reversed by the addition of vanadate to the drinking water [7] [8] [9] , vanadate may be a useful tool for studying the mechanisms of insulin resistance. In addition, we recently demonstrated that vanadate treatment of rat adipocytes augments insulin binding and sensitivity both in normal and insulin-resistant cells [10] . The possible clinical use of vanadate in insulin-resistant states has also attracted great interest. In a recent study [11] , it was demonstrated that vanadate in combination with H202 forms peroxovanadate and that both vanadate and peroxovanadate increase the insulin receptor tyrosine kinase and exert insulin-like effects in rat adipocytes. In the same study it was shown that peroxovanadate was more potent than vanadate [11] . This was also recently confirmed in muscle from insulin-resistant animals [12] .
In the present study, the effect of vanadate and peroxovanadate was for the first time studied in normal human adipocytes isolated from the subcutaneous fat.
Materials and methods
Adipose tissue biopsies." Biopsies (3-5 g) of subcutaneous adipose tissue were removed from subjects undergoing elective surgery for cholelithiasis. The biopsies were obtained immediately after anaesthesia and placed in a vessel containing medium 199 (Statens Bakteriologiska Laboratorium, Stockholm, Sweden) at 37 ~ The subjects were otherwise healthy and none was taking any regular medication. Their informed consent was obtained and the study was approved by the Ethics Committee of the University of G6teborg.
Isolation of adipose cells:
Dissected tissue pieces (-5 mg) were incubated at 37 ~ in medium 199 containing 4 % bovine albumin (Sigma, St. Louis, Mo., USA) and i mg/ml collagenase (Sigma) in a shaking water bath. After approximately 50 rain, liberated cells were filtered through a nylon mesh and washed four times in fresh albumin-containing medium containing 1 U/ml adenosine deaminase (ADA; Boehringer Mannheim, Mannheim, FRG).
Lipolysis: Isolated cells, lipocrit 1-3 %, were incubated at 37 ~ the presence of 1 U/ml adenosine deaminase (ADA) with or without isoproterenol, N6-monobutyryl-cAMP (Sigma), insulin (Novo Nor- Insulin-like effects ofperoxovanadate bated as described above. After 2 h at 16 ~ the cells were separated from the incubation medium and radioactivity counted. Tracer bound in the presence of 0.7 gmol/1 unlabelled insufin was considered non-specific and was subtracted.
Preparation of vanadate and peroxovanadate: Sodium orthovanadate (Sigma) was dissolved in medium 199 to a final concentration of 10 mmol/1 and pH adjusted to 7.4 with i mol/1HC1 at 37 ~ [11] . Peroxovanadate was generated by mixing 1 mmol/1H2Oz and 10 mmol/l vanadate. After 15 min at room temperature, catalase (Sigma) was added to a final concentration of 200 gtg/ml for a further 15 min to remove free H202 [11] . disk, Copenhagen, Denmark), vanadate or peroxovanadate at the indicated concentrations for 1 h. The incubation was stopped by centrifuging the cells through silicone oil. The glycerol content of the incubation medium was analysed [13] and taken as an index of lipolysis. Cell size and number were measured as previously described [14] .
Statistical analysis
14C-U-glucose uptake: Cellular uptake of 14C-U-glucose (New England Nuclear, Boston, Mass., USA) at a tracer concentration (0.3 mmol/1, 0.2 gCi/tube) was measured during 1-h incubation of cells in glucose-free medium following pre-incubation in the absence or presence of insulin for 15 min. After separation from the incubation medium, the cells were put into scintillation fluid and the radioactivity counted. The cellular clearance of medium glucose was calculated according to the formula:
(cpm cells) / (cpm medium) x (cell number) x s and taken as an index of the rate of glucose uptake [15] .
125I-insulin binding:
Following the addition of 2 mmol/1 KCN (to stop 125 receptor cycling) 200 pg/ml I-insulin (60-90 nCi/tube, Novo Nordisk) and 0-0.7 gmol/1 tmlabelled insulin was added to cells incuThe statistical significance of differences was tested with Student's t-test for paired observations.
Results

Glucose uptake
Figure 1shows the effect of insulin, vanadate and peroxovanadate on a4c-U-glucose uptake. Insulin at 1000 gU/ml stimulated 14C-U-glucose uptake approximately 2.5-fold and 0.1 mmol/1 peroxovanadate completely mimicked this effect of insulin. Surprisingly, vanadate alone was ineffective at any concentration tested (0.05-10 mmol/1). No additive response was seen by combining 0.1 mmol/1 peroxovanadate and 1000 gU/ml insulin. Control experiments confirmed that sodium orthovanadate alone exerted a full insulin-like effect in rat adipocytes (data not shown).
The dose-response curve for the stimulatory effect of peroxovanadate on 14C-U-glucose uptake is shown in Figure 2 . The half-maximal effect of peroxovanadate was seen at 0.05 mmol/1. The dose-response curve was markedly biphasic and basal levels of 14C-U-glucose uptake were seen at peroxovanadate concentrations of 2 mmol/1 and above. Vanadate did not exert any response at any concentration.
The dose-response curve for the effect of insulin on 14C-U-glucose uptake was not altered by either vanadate (2 or 5 mmol/1) or peroxovanadate (0.05 or 0.1 mmol/1). 125I-insulin binding was not consistently changed by either of these agents (data not shown).
Antilipolytic effect
Neither insulin nor vanadate alone or in combination with H202 exerted any antilipolytic effect in the absence of lipolytic agents (data not shown). When lipolysis was stimulated by N6-monobutyryl cAMR a cAMP analogue which is not hydrolysed by the phosphodiesterase [16] , no antilipolytic effect was exerted by any of the three agents (Fig. 3) . However, when lipolysis was stimulated by isoproterenol (1 gmol/1) insulin decreased the lipolysis rate by about 50 %. Peroxovanadate at 2 mmol/1 was equally effective, whereas vanadate was ineffective at any concen- tration tested, up to concentrations as high as 10 mmol/1 (Fig 9 3 ).
Discussion
In this study the effect of vanadate and peroxovanadate was tested for the first time in a human cell type, the human subcutaneous adipocyte. The data clearly show that, unlike the rat adipocyte, these cells are unresponsive to vanadate under these conditions. Neither insulin responsiveness nor sensitivity was altered by the addition of vanadate and vanadate itself did not exert an insulin-like activity. To exclude the possibility that this was due to problems with the preparation of the vanadate solution, control experiments were performed with isolated rat adipocytes. These clearly showed that the vanadate used exerted a normal insulin-like effect on 14C-U-glucose uptake in these cells (data not shown) 9 Thus, it may be concluded that, under the present conditions, vanadate was not effective in human adipocytes. However, it should be noted that the insulin-like activity was only assessed in acute experiments and the present data do not therefore exclude the possibility that vanadate may have long-term effects as previously demonstrated in experimental animals [7] [8] [9] . Although vanadate does not exert insulin-like effects in human adipocytes, these cells appear to be readily responsive to peroxovanadate. A full insulin-like response was exerted at low concentrations of peroxovanadate when the effects of a4C-U-glucose uptake and lipolysis were measured. However, no additive effect of peroxovanadate was exerted in combination with a maximal concentration of insulin. This is in contrast to the recent study with rat adipocytes of Kadota et al. [17] , where peroxovanadate further increased the recruitment of insulinlike growth factor (IGF) II-receptors to the cell surface in the presence of a maximal concentration of insulin [17] . Furthermore, human and rat adipose cells seem to respond differently to peroxovanadate since, as demonstrated in the present study, the dose-response curve for peroxovanadate was markedly biphasic in human fat cells and the insulin-like activity was seen only over a narrow concentration range 9 This has not been reported with rat adipocytes [11, 17] . The reason for this biphasic response in human fat cells is not fully clear 9 However, control studies with human fat cells in our laboratory have shown that vanadate dose-dependently inhibits the effect of peroxovanadate (data not shown). Thus, free vanadate seems to compete with peroxovanadate at the appropriate sites of action 9 It is unlikely that high concentrations of peroxovanadate exerts a toxic effect since the antilipolytic effect of pervanadate remained even at 2 mmol/1.
The mechanism by which vanadate exerts its insulinlike effects in rat adipocytes is not clear [3] . However, the demonstration that insulin binding to the insulin receptor leads to autophosphorylation of the receptor fl-subunit [18] which subsequently expresses tyrosine kinase activity [19] , suggests an important effect of the phosphotyrosine phosphatase inhibition for the action of vanadate. In agreement with this possibility, it has been shown that activation of the insulin receptor tyrosine kinase by vanadate correlates with the insulin effect on IGF-II receptor binding [11, 17] . In contrast, such a relationship between the receptor tyrosine kinase and the antilipolytic effect of vanadate was not evident in two recent studies [20, 21] . Thus, it is not clear that vanadate exerts its insulin-like activity by increasing the insulin receptor tyrosine kinase activity 9 An alternative explanation for the insulin-like effect of vanadate may be that vanadate stimulates NADH oxidase and, thus, increases H202 formation inside the cells [22] . H202 is capable of exerting insulin-like activity in adipocytes [23] . Moreover, since vanadate readily enters the cells intracellular formation of peroxovanadate may take place 9 However, such an effect is then obviously deficient in human fat cells since they are unresponsive to vanadate alone 9 Whatever the mechanism of action of peroxovanadate, this agent is more efficient than vanadate as a mimic of the effects of insulin in human adipocytes. It should be noted, however, that the mechanism by which peroxovanadate and insulin exert their effects in human adipocytes may share the same signalling pathway(s) since no additive effect in combination with insulin was seen. Furthermore, peroxovanadate effectively inhibited catecholamine-stimulated lipolysis, as insulin does, but did not inhibit lipolysis stimulated by the non-hydrolysable cAMP analogue N6-monobutyryl-cAMP, suggesting that the antilipolytic effect by both agents is exerted by the activation of the phosphodiesterase [24] .
It was recently reported that insulin binding to rat adipocytes is increased in the presence of vanadate [25] . Ex-periments on rat adipocytes in our laboratory have shown that vanadate increased the number of binding sites for insulin at the cell surface and, in parallel, shifted the doseresponse curve for insulin to the left [10] . However, in the present study with human fat cells no such effect was exerted by vanadate or, consistently, by peroxovanadate.
In summary, the present study shows that no insulinlike effect is exerted by vanadate in human subcutaneous adipocytes, whereas peroxovanadate is highly effective, giving a full insulin-like response at a low concentration. Future investigations focused on mechanisms of action as well as the long-term effect of peroxovanadate in vivo in animal models of diabetes or other manifestations of insulin resistance would be of obvious interest. However, such studies would require the availability of stable peroxovanadate preparations. Such compounds are now being developed and should provide us with useful tools to explore the insulin signalling mechanism.
